Stéphane Gagné, M.Sc., President & CEO – Ovensa Inc.
Co-Founder of Ovensa and three other companies, Mr. Gagné holds 20 years of experience in the pharmaceutical (anticancer drugs and drug delivery), cosmetics and nutritional supplements industries. He was instrumental to the growth of Aeterna-Zentaris, a company that was developing an angiogenesis inhibitor for non-small cell lung cancer. He was also a co-founder of Constab Pharmaceutical, a company developing a drug delivery system using alpha-fetoprotein. Mr. Gagné also contributed to the international expansion of Atrium Biotechnologies and several Canadian private and public companies. He is recognized for his leadership, for building teams, growing sales and for his negotiation skills. He holds 2 bachelor degrees (Economics and Multidisciplinary), has a Master Degree in Business Administration and speaks several languages.
Steven Splinter, Ph.D.CTO & Director
Radient Technologies Inc.
Steven Splinter, Ph.D., CTO & Director - Radient Technologies Inc.
A science entrepreneur with over 18 years of corporate, strategic and operational experience (13 years in Executive or Senior Management roles). Successfully founded, raised investment rounds and led initial corporate and all technical development for an agri-based bio-innovation company. Experienced in strategic planning, technical assessment and development of process technologies, business leadership, and engineering project management.
Neil Klompas, CPA, CAEVP Business Operations & CFO
Neil Klompas, CPA, CA, EVP Business Operations & CFO – Zymeworks
Mr. Klompas is the Executive Vice President and Chief Financial Officer of Zymeworks Inc. (NYSE: ZYME), a clinical stage biotechnology company based in Vancouver. Neil brings over 20 years of healthcare and biotechnology experience. Prior to joining Zymeworks in 2007 he worked with KPMG LLP in Canada and the United States, including with KPMG’s Pharmaceutical, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on numerous transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas is a Chartered Professional Accountant and is a member of Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia and currently serves on the board of Liminal BioSciences Inc. (NASDAQ/TSX: LMNL), and on the faculty advisory board for Biotechnology and Chemistry for Camosun College. He formerly served as a Director for the Canadian Gene Cure Foundation, and currently assists the Canadian Cancer Society on initiatives in British Columbia.
Kathleen Ngassam obtained a Bachelor in Chemical Engineering from McGill University in 1993. In parallel to starting her engineering career, she subsequently completed a Graduate Diploma in Project Management at École Polytechnique de Montréal, followed by an MBA from the Hautes Études Commerciales de Montréal. Further seeking to combine active business practice with academic knowledge, she completed, earlier this year, a Doctorate in Business Administration degree with the University of Liverpool (U.K.).
Kathleen spent the first 17 years of her professional career working in the pharmaceutical industry with companies such as ICN, Abbott, DSM Biologics and Pfizer. Over this period, she had the opportunity to work and gain significant experience in different areas of the business including manufacturing, quality assurance, product development, project management, government affairs, as well as marketing. In 2011, Kathleen undertook the challenge of changing both industries and scale of enterprise, by joining Solumet, a growing diversified metals recycling and trading company, in the capacity of project manager. An active member of Anges Québec since 2016, with a specific interest in Life Sciences and Impact investing, she is also on the board of two other companies in the Anges Quebec portfolio
Manon Boisclair is the Chief Commercial Officer at Syantra, a precision medicine company developing an innovative liquid biopsy platform for early detection of cancers. She is also an entrepreneur and founder of InnovID B2, a boutique consultancy firm for life science companies. Manon has 15 years of international experience in executive management roles with NASDAQ-listed BioPharma companies (Merck, Novartis, Celgene and Intercept) in the US, Canada and Europe. She has extensive global operations and go-to- market medical/marketing strategy expertise having worked on several blockbusters as well as early pipeline compounds across therapeutic areas. Involved in private equity, Manon is a seasoned angel investor with a solid track record in business development, governance, and Series A & B fundraising. Manon is currently an independent board director of two privately owned companies- Ovensa and MedHelper as well as board director for nonprofit organizations including the Canadian Cancer Society and Canada College. Active in the startup ecosystem, Manon is a mentor to several MedTech entrepreneurs affiliated with CDL and Centech as well as a strategic advisor to Eli Health, PerceiveAI, Ditch Labs, and Eyful. Manon has a master’s degree in nursing from University of Montreal, an executive MBA from McGill/HEC Montreal, she is a certified corporate board director from Harvard Business School and the Institute of Corporate Directors.